A lack of consensus guidelines or a belief that current evidence does not support such guidelines might be justified if a clinician expresses a commitment to patient-centered care and shared decision making.
AMA J Ethics. 2018; 20(11):E1007-1016. doi:
10.1001/amajethics.2018.1007.
Parents’ false beliefs can be engaged respectfully to motivate deliberations about shared values and goals, but refusal of clinically indicated treatment could warrant reporting.
AMA J Ethics. 2018; 20(11):E1017-1024. doi:
10.1001/amajethics.2018.1017.
Stephanie L. Samuels, MD and Wilma C. Rossi, MD, MBE
When a parent resists a physician's recommendation for a pediatric patient, physician-parent partnering can promote the patient's best interest and help encourage lifestyle changes.
AMA J Ethics. 2018; 20(12):E1126-1132. doi:
10.1001/amajethics.2018.1126
Rachel Koch, MD, John G. Meara, MD, DMD, MBA, and Anji E. Wall, MD, PhD
Single-procedure interventions with minimal follow-up and clear quality-of-life gain are well suited for surgical mission trips. But not all risks and benefits are easily assessed.
AMA J Ethics. 2019; 21(9):E729-734. doi:
10.1001/amajethics.2019.729.
How do we determine what a fair price for a life-saving prescription medication should be? This month, we discuss what is means for a price to be “fair” and explore the current legal and economic landscape of prescription drug pricing in the US.
Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019; 21(10):E844-851. doi:
10.1001/amajethics.2019.844.